Business Context and Reporting Period
This Form 8-K Current Report was filed by AngioDynamics, Inc. on March 30, 2007, covering events reported on March 28, 2007. The filing addresses significant changes in the company's executive leadership structure, specifically regarding the Chief Financial Officer role.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements.
- New CFO Base Salary: $235,000 annually.
- Bonus Opportunity: Up to 35% of base salary.
- Signing Bonus: $25,000 cash.
- Equity Grants (Effective May 1, 2007):
- 40,800 stock options (vesting 25% annually over four years).
- 1,126 restricted stock units (vesting May 30, 2009).
- 1,126 performance shares (vesting 50% annually starting 2008, contingent on revenue and EPS targets).
Material Changes
Effective April 16, 2007, the company will undergo the following leadership transitions:
- Joseph G. Gerardi: Transitioning from Vice President, Chief Financial Officer, and Treasurer to Vice President, Special Projects. His new focus includes integrating the recent acquisition of RITA Medical Systems, Inc.
- D. Joseph Gersuk: Appointed as Senior Vice President and Chief Financial Officer. He will oversee financial operations and strategy, reporting directly to CEO Eamonn P. Hobbs.
Outlook, Risks, and Management Commentary
Management commentary indicates a strategic shift to support the integration of the RITA Medical Systems acquisition and to drive future growth opportunities. The appointment of Mr. Gersuk is intended to provide strategic input on expansion. The filing does not explicitly list new risks or contingencies beyond the standard vesting conditions for the new executive's equity awards.
Investor Verification Checklist
- Confirm the effective date of the CFO transition (April 16, 2007).
- Verify the specific revenue and earnings per share targets required for the vesting of Mr. Gersuk's performance shares.
- Review the integration progress of the RITA Medical Systems, Inc. acquisition under Mr. Gerardi's new role.
- Check the Nasdaq closing price on May 1, 2007, to determine the exercise price for the 40,800 stock options granted to Mr. Gersuk.